Indications for: FIRVANQ

C. difficile-associated diarrhea. Enterocolitis due to S. aureus.

Limitations of Use:

Oral vancomycin HCl not effective for treatment of other types of infections.

Adult Dosage:

C. difficile-associated diarrhea: 125mg 4 times a day for 10 days. Enterocolitis: 500mg–2g per day in 3–4 divided doses for 7–10 days.

Children Dosage:

40mg/kg per day in 3–4 divided doses for 7–10 days; max 2g/day.

FIRVANQ Warnings/Precautions:

Renal insufficiency and/or colitis. Inflammatory bowel disorders. Underlying hearing loss. Monitor hearing, blood, renal function. Consider monitoring vancomycin serum concentrations. Discontinue at the 1st sign of skin rashes, mucosal lesions, blisters. Not for endophthalmitis prophylaxis. Elderly. Pregnancy. Nursing mothers.

FIRVANQ Classification:


FIRVANQ Interactions:

Monitor with aminoglycosides, other neurotoxic, nephrotoxic, or ototoxic drugs.

Adverse Reactions:

Nausea, abdominal pain, hypokalemia; ototoxicity, nephrotoxicity, superinfection, severe dermatologic reactions (eg, TEN, SJS, DRESS, AGEP, LABD).

Generic Drug Availability:


How Supplied:

Kit—1 (w. diluent)